158 related articles for article (PubMed ID: 11895878)
1. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial.
Sample DA; Sinicrope PS; Wargovich MJ; Sinicrope FA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):281-5. PubMed ID: 11895878
[TBL] [Abstract][Full Text] [Related]
2. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.
Krishnan K; Ruffin MT; Normolle D; Shureiqi I; Burney K; Bailey J; Peters-Golden M; Rock CL; Boland CR; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):447-53. PubMed ID: 11352853
[TBL] [Abstract][Full Text] [Related]
3. Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial.
Sandler RS; Halabi S; Kaplan EB; Baron JA; Paskett E; Petrelli NJ
Cancer; 2001 Mar; 91(5):1040-5. PubMed ID: 11251957
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
6. Measurement of factors influencing the participation of patients with prostate cancer in clinical trials: a Canadian perspective.
Davison BJ; So A; Goldenberg SL; Berkowitz J; Gleave ME
BJU Int; 2008 Apr; 101(8):982-7. PubMed ID: 18005198
[TBL] [Abstract][Full Text] [Related]
7. Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study.
Costenbader KH; Brome D; Blanch D; Gall V; Karlson E; Liang MH
Arthritis Rheum; 2007 Feb; 57(1):49-55. PubMed ID: 17266094
[TBL] [Abstract][Full Text] [Related]
8. Identifying motivations and barriers to patient participation in clinical trials.
Jones JM; Nyhof-Young J; Moric J; Friedman A; Wells W; Catton P
J Cancer Educ; 2006; 21(4):237-42. PubMed ID: 17542716
[TBL] [Abstract][Full Text] [Related]
9. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker.
Sample D; Wargovich M; Fischer SM; Inamdar N; Schwartz P; Wang X; Do KA; Sinicrope FA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):275-9. PubMed ID: 11895877
[TBL] [Abstract][Full Text] [Related]
10. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
11. [Chemopreventive agents in colorectal cancer].
Benamouzig R; Chaussade S
Rev Prat; 2003 Dec; 53(20):2213-4. PubMed ID: 15018072
[No Abstract] [Full Text] [Related]
12. The association between aspirin use and the incidence of colorectal cancer in women.
Allison M; Garland C; Chlebowski R; Criqui M; Langer R; Wu L; Roy H; McTiernan A; Kuller L;
Am J Epidemiol; 2006 Sep; 164(6):567-75. PubMed ID: 16847042
[TBL] [Abstract][Full Text] [Related]
13. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret.
Stryker JE; Wray RJ; Emmons KM; Winer E; Demetri G
Patient Educ Couns; 2006 Oct; 63(1-2):104-9. PubMed ID: 16242898
[TBL] [Abstract][Full Text] [Related]
14. Dietary fat and fatty acids and risk of colorectal cancer in women.
Lin J; Zhang SM; Cook NR; Lee IM; Buring JE
Am J Epidemiol; 2004 Nov; 160(10):1011-22. PubMed ID: 15522858
[TBL] [Abstract][Full Text] [Related]
15. Causal relationship between health promoting behavior and quality of life in cervical cancer patients undergoing radiotherapy.
Taechaboonsermsak P; Kaewkungwal J; Singhasivanon P; Fungladda W; Wilailak S
Southeast Asian J Trop Med Public Health; 2005 Nov; 36(6):1568-75. PubMed ID: 16610663
[TBL] [Abstract][Full Text] [Related]
16. [Clinical trials--viewpoints from participants].
Langslet G; Ottestad I; Retterstøl K; Ose L
Tidsskr Nor Laegeforen; 2010 Aug; 130(16):1606-8. PubMed ID: 20805857
[TBL] [Abstract][Full Text] [Related]
17. Pilot trial of a computerized decision aid for breast cancer prevention.
Ozanne EM; Annis C; Adduci K; Showstack J; Esserman L
Breast J; 2007; 13(2):147-54. PubMed ID: 17319855
[TBL] [Abstract][Full Text] [Related]
18. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
19. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
20. Self-reported colonoscopy screening in Austria.
Haidinger G; Waldhoer T; Vutuc C
Eur J Cancer Prev; 2008 Aug; 17(4):354-7. PubMed ID: 18562961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
